Top

The journal of nutrition, health & aging

Published in:

01-02-2020 | Prostate Cancer

HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer

Published in: The journal of nutrition, health & aging | Issue 2/2020

Abstract

Background

Sarcopenia is a muscle disease defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. In addition to aging, many factors may contribute to sarcopenia as cancer and/or androgen deprivation therapy (ADT).

Objectives

The aims of this study are to describe the prevalence of sarcopenia in older prostate cancer patients before initiation of treatment with ADT and radiotherapy, and to evaluate the impact of ADT on the occurrence or aggravation of sarcopenia in this population.

Design

Longitudinal study.

Participants and setting

Sarcopenia was prospectively evaluated in 31 consecutive patients aged 70 to 88 years, referred in one hospital unit of south eastern France, for a comprehensive geriatric assessment (CGA) before cancer treatment initiation.

Measurements and results

CGA, measures of muscle strength and physical performances were performed at baseline (T0) and at the end of cancer treatment (T1). Appendicular skeletal muscle mass was measured by Dual-energy X-ray absorptiometry (DXA) at the end of treatment. At T0, 8 patients (among 31) had a probable sarcopenia according to European consensus, and 18 had altered physical performance. At T1, 15 patients (among 19) had abnormal one leg balance test. Finally, only one patient had a sarcopenia confirmed by DXA.

Conclusion

This preliminary study showed a high prevalence of muscle disorders before initiation of ADT in a population of elderly cancer prostate patients with intermediate frailty status, and an increased risk of falls at the end of ADT. This highlighted the importance of screening for sarcopenia before treatment initiation, to prevent the occurrence or aggravation of sarcopenia by possible adjustment of treatment, and implementation of appropriate exercise and nutrition interventions.

Rebillard X, Grosclaude P, Leone N, et al. [Incidence and mortality of urological cancers in 2012 in France]. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 2013;23 Suppl 2:S57–65.CrossRef

Mottet N, van den Bergh RCN, Briers E et al, 2018. EAU - ESUR - ESTRO - SIOG Guidelines on prostate cancer 2018 - European association of urology 2018. https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf Accessed August 2019

Hmadi H and Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Related Outcome Measures 2014;5:63–70.

Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. International Journal of Urology 2018;25:45–53CrossRefPubMed

Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16–31.CrossRefPubMed

Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12(4):249–56.CrossRefPubMed

Chen L-K, Liu L-K, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014;15(2):95–101.CrossRefPubMed

American Society of Hand Therapists (ASHT). Clinical Assessment recommendations -3rd edition, P.1-20. Consultable en ligne: http://ahint.epubxp.com/i/582310-3rd-edition-2015-17.

Friedman PJ, Richmond DE, Baskett JJ. A prospective trial of serial gait speed as a measure of rehabilitation in the elderly. Age Ageing 1988;17(4): 227–235.CrossRefPubMed

10.

Podsiadlo D, Richardson S. The timed up and go: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39: 142–148.CrossRefPubMed

11.

Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PloS One 2014;9 (12): e115060.CrossRefPubMedPubMedCentral

12.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1998;25 (6): 649–655.CrossRef

13.

Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL, a standardized measure of biological and psychological function. JAMA 1963;185: 914–919.CrossRefPubMed

14.

Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9: 179–186.CrossRefPubMed

15.

Vellas BJ, Sharon J, Wayne MS et al. One-Leg Balance is an important predictor of injurious falls in older persons. J Am Geriatr Soc 1997;45 (6):735–738.CrossRefPubMed

16.

Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med 2002;18(4):737–757.CrossRefPubMed

17.

HAS quick reference guide 2007. Nutritional support strategy for protein-energy malnutrition in the elderly. https://www.has-sante.fr/upload/docs/application/pdf/malnutrition_elderly_quick_ref_guide.pdf Accessed August 2019

18.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189–198.PubMed

19.

Reijnierse EM, Trappenburg MC, Leter MJ et al. The impact of different diagnostic criteria on the prevalence of sarcopenia in healthy elderly participants and geriatric outpatients. Gerontology 2015;61:491–496.CrossRefPubMed

20.

Moreira VG, Perez M, Lourenço RA. Prevalence of sarcopenia and its associated factors: the impact of muscle mass, gait speed, and handgrip strength reference values on reported frequencies. Clinics, 2019; DOI:https://doi.org/10.6061/clinics/2019/e477.

21.

Cruz-Jentoft A, Landi F, Schneider SM et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and Ageing 2014;43: 748–759.CrossRefPubMedPubMedCentral

22.

Shimokata N, Shimada H, Satake S et al. Epidemiology of sarcopenia. Geriatr Gerontol Int 2018;18 (Suppl. 1): 13–22.CrossRefPubMed

23.

Walston J, Hadley EC, Ferrucci L, et al. Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006;54: 991–1001.CrossRefPubMed

24.

Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sco Med Sci 2001;56: M146–M156.CrossRef

25.

Winters-Stone KM, Moe E, Graff JN et al. Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy. J Am Geriatr Soc 2017;65 (7): 1414–1419.CrossRefPubMedPubMedCentral

26.

Wu FJ, Sheu SY, Lin HC, Chung SD. Increased fall risk in patients receiving androgen deprivation therapy for prostate cancer. Urology 2016;95: 145–150.CrossRefPubMed

27.

Alibhai SMH, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010;28:5038–5045.CrossRefPubMed

28.

Smith MR, Saad F, Egerdie B et al. Sarcopenia during androgen deprivation therapy for prostate cancer. J Clin Oncol 2012;30: 3271–3276.CrossRefPubMedPubMedCentral

29.

Dawson JK, Dorff TB, Schroeder ET et al. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer 2018;18:368 doi https://doi.org/10.1186/s12885-018-4306-9 CrossRefPubMedPubMedCentral

30.

Lester-Coll NH, Goldhaber SZ, Sher DJ, D’Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis. Cancer 2013;119(10):1808–1815.CrossRefPubMed

Title: HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer
Publication date: 01-02-2020
Keywords: Prostate Cancer
Sarcopenia
Prostate Cancer
Radiotherapy
Androgens
Published in: The journal of nutrition, health & aging / Issue 2/2020
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI: https://doi.org/10.1007/s12603-019-1294-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer

Abstract

Background

Objectives

Design

Participants and setting

Measurements and results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objectives

Design

Participants and setting

Measurements and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Association between Dietary Protein Intake and Cognitive Function in Adults Aged 60 Years and Older

Prevalence of Malnutrition in Older Hospitalized Cancer Patients: A Multicenter and Multiregional Study

The Magic of Spells

Sensory Impairment and All-Cause Mortality Among the Oldest-Old: Findings from the Chinese Longitudinal Healthy Longevity Survey (CLHLS)

Prevalence of Cognitive Frailty Phenotypes and Associated Factors in a Community-Dwelling Elderly Population

The Adverse Effects of Physical Restraint Use among Older Adult Patients Admitted to the Internal Medicine Wards: A Hospital-Based Retrospective Cohort Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page